Breakthrough in COVID-19 Research: Scientists Discover Potential New Drug and Platform for Finding Medicines Against Infectious Diseases

Strategic Insights -

Scientists at The Wertheim UF Scripps Institute have made a significant breakthrough in the development of a new antiviral drug against COVID-19 and other diseases. A collaboration led by Matthew D. Disney, Ph.D., and his team devised a powerful new platform for finding medicines to fight many types of infectious diseases. The team identified a potential new drug, dubbed Compound 6, which targets the SARS-CoV-2 virus by misfolding and malfunctioning viral proteins, ultimately leading to their destruction and removal by cells.

Key Takeaways:

  • The team developed a powerful new platform for finding medicines to fight many types of infectious diseases, including COVID-19, influenza, norovirus, MERS, Marburg, Ebola, and Zika.
  • Compound 6, a refined and optimized compound, targets the SARS-CoV-2 virus by misfolding and malfunctioning viral proteins, leading to their destruction and removal by cells.
  • The method can be applied to any number of RNA-based viruses that burden society and have limited treatment options.
  • The team has already started work on several of these viruses, including norovirus, and plans to extend this strategy to other high-priority RNA targets.
  • The collaboration involved experts from The Wertheim UF Scripps Institute, Skaggs-Calibr Institute for Innovative Medicines, and the NIH's initiative to rebuild the nation's antiviral medicine cabinet.
  • The platform represents a transformative way of thinking about drug discovery, offering a directed and unbiased way to rationally design RNA-targeting antiviral small-molecule medications.

Statistics:

  • The SARS-CoV-2 virus is so tiny it would take 1,000 of them lined end-to-end to equal the width of a typical human hair.
  • The virus generates 27 proteins, with one mechanism called a frameshift element enabling efficient use of the tight viral real estate.
  • The team used both computational and experimental approaches to find the right chemical probes that would allow them to map the frameshift element's binding pockets and mutations.
  • Compound 6 had the optimal impact in experiments on live cells infected with SARS-CoV-2, demonstrating its antiviral activity.
  • The team is developing strategies to boost the potency and effectiveness of Compound 6.

Sources:

  • "A Generalizable Strategy for Complementing RNA Structural Biology with Small Molecule Development," Journal of the American Chemical Society, online article posted on Monday, Oct. 6, 2025.
  • NIH's initiative to rebuild the nation's antiviral medicine cabinet, through the AViDD program.
  • The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology.
  • The Skaggs-Calibr Institute for Innovative Medicines.
  • Scripps Research, part of the National Institutes of Health's initiative.